Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Second Line Treatment”

1,321 trials

Showing 20 of 1,321 results

Not applicableStudy completedNCT02727582
What this trial is testing

Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment

Who this might be right for
Multidrug-resistant Tuberculosis
University of Cape Town 142
Testing effectiveness (Phase 2)Study completedNCT01386242
What this trial is testing

Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 108
Testing effectiveness (Phase 2)Ended earlyNCT00595985
What this trial is testing

Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Fudan University 5
Testing effectiveness (Phase 2)Looking for participantsNCT06309485
What this trial is testing

Phase 2 Study of WGI-0301 for Advanced HCC

Who this might be right for
Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd. 60
Testing effectiveness (Phase 2)UnknownNCT03144843
What this trial is testing

Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.

Who this might be right for
Gastric Cancer
Sun Yat-sen University 110
Post-approval studies (Phase 4)Not Yet RecruitingNCT06499610
What this trial is testing

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
First Affiliated Hospital Xi'an Jiaotong University 44
Early research (Phase 1)UnknownNCT01454479
What this trial is testing

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Who this might be right for
Recurrent Endometrial Cancer
Hung-Hsueh Chou 24
Large-scale testing (Phase 3)Study completedNCT00486954
What this trial is testing

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Who this might be right for
Neoplasms, Gastrointestinal Tract
GlaxoSmithKline 273
Not applicableStudy completedNCT05214573
What this trial is testing

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Who this might be right for
Type 2 DiabetesCardiac Disease
Mayo Clinic 386,301
Testing effectiveness (Phase 2)Study completedNCT04770623
What this trial is testing

Docetaxel and Irinotecan in Gastric Cancer

Who this might be right for
Stomach CancerGastric CancerChemotherapy Effect
Menoufia University 32
Large-scale testing (Phase 3)Looking for participantsNCT05768503
What this trial is testing

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Who this might be right for
Metastatic Microsatellite-stable Colorectal Cancer
Sun Yat-sen University 176
Testing effectiveness (Phase 2)UnknownNCT02665702
What this trial is testing

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Who this might be right for
Esophageal Squamous Cell Carcinoma
Fudan University 76
Not applicableStudy completedNCT00668083
What this trial is testing

Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
AstraZeneca 214
Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592612
What this trial is testing

Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment

Who this might be right for
Hepatocellular CarcinomaOligoprogression
Sun Yat-sen University 70
Large-scale testing (Phase 3)Study completedNCT01168973
What this trial is testing

Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 1,253
Large-scale testing (Phase 3)Study completedNCT01878422
What this trial is testing

Sequential Treatment Strategy for Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 376
Not applicableUnknownNCT03531931
What this trial is testing

Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

Who this might be right for
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety
The First Affiliated Hospital of Xiamen University 20
Testing effectiveness (Phase 2)WithdrawnNCT03843853
What this trial is testing

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
The First Affiliated Hospital with Nanjing Medical University
Large-scale testing (Phase 3)Study completedNCT02259127
What this trial is testing

ODYSSEY (PENTA 20)

Who this might be right for
HIV Infection
PENTA Foundation 792
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation